Search all of our press releases here.
ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ – American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of… [Read More]
ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing… [Read More]
ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company’s technology, including AGT103-T, a therapeutic intended to cure HIV, which… [Read More]
ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown… [Read More]
ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), regarding AGT’s promising cell and gene therapy for HIV. Through a collaboration… [Read More]
Click on images to view larger ROCKVILLE, Md., July 28, 2020 — American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from National Cancer Institute and Johns Hopkins Shady Grove Campus. The new facility will support AGT’s… [Read More]
ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston, MA on March 11, 2020. Dr. Pauza will present how AGT used its proprietary, lentiviral… [Read More]
ROCKVILLE, MD, January 8, 2020 – American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the 38th annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 12-16 in San Francisco, California. American Gene Technologies’ second invitation to attend the conference follows its continued discussions with J.P. Morgan and other biotechnology investment… [Read More]
Press release also featured on: GlobeNewswire.com ROCKVILLE, MD, November 06, 2019 – American Gene Technologies (AGT) announced today it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully submitted its Investigational New Drug (IND) application to the Food & Drug Administration (FDA) to… [Read More]
ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the disease. “Our aim is to treat HIV disease with an innovative cell and gene therapy… [Read More]
Subscribe to our press release and published article updates to be notified when we release new content!